JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on Bayer (FRA:BAYN) in a research note released on Tuesday. The firm currently has a buy rating on the healthcare company’s stock.

A number of other analysts have also commented on the stock. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the company a buy rating in a research note on Friday, August 17th. Deutsche Bank set a €137.00 ($159.30) target price on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, August 22nd. DZ Bank reiterated a neutral rating on shares of Bayer in a research note on Friday, August 24th. Berenberg Bank set a €113.00 ($131.40) target price on shares of Bayer and gave the stock a buy rating in a research note on Monday, August 27th. Finally, Independent Research set a €95.00 ($110.47) target price on shares of Bayer and gave the stock a neutral rating in a research note on Monday, August 13th. Nine investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of €100.02 ($116.31).

Shares of BAYN stock opened at €73.81 ($85.83) on Tuesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.